Appointment of Dr. med. Jan-Henrik Terwey as Chief Scientific Officer

We are pleased to announce the appointment of Dr. med. Jan-Henrik Terwey as Chief Scientific Officer (CSO) and Member of the Executive Board of the Swiss Cancer Institute as of March 2026.

Jan brings more than 20 years of international leadership experience in the biopharmaceutical industry, with a strong focus on clinical development and medical affairs in both solid tumors and hematology. In addition to his extensive industry background, he contributes valuable clinical expertise as a trained physician. Following clinical work in anesthesiology, he has held various leadership positions in Switzerland since 2005 at Amgen and later at Atara Biotherapeutics, including serving as Early Clinical Development Lead for an allogeneic CAR T-cell therapy program. Most recently, he led the European medical organization as Head of Medical Affairs Europe at BeOne Medicines.

As CSO, he will assume overall leadership of the Clinical Science Department and play a key role in shaping the scientific and strategic development of the Institute.

We would also like to sincerely thank PD Dr. Roch Philippe Charles for his outstanding commitment as former CSO. In his new role as Senior Scientific Director, he will remain closely involved with the Clinical Science Department and continue to contribute his extensive expertise.

We warmly welcome Jan and look forward to working together.